Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Drug Interaction Study to Evaluate the Safety, Tolerability and Effect on Atorvastatin Pharmacokinetics of ETC-1002 Added to Atorvastatin 10 mg/Day in Subjects With Hypercholesterolemia

NCT01779453 is registered in ClinicalTrials.gov with Esperion Therapeutics, Inc. as lead sponsor.

NCT NCT01779453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01779453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Drug Interaction Study to Evaluate the Safety, Tolerability and Effect on Atorvastatin Pharmacokinetics of ETC-1002 Added to Atorvastatin 10 mg/Day in Subjects With Hypercholesterolemia
Lead sponsor
Esperion Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
August 31, 2013
Enrollment
58 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia